Cargando…
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review
Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension. We reviewed published data on the effects of phos...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951021/ https://www.ncbi.nlm.nih.gov/pubmed/29256324 http://dx.doi.org/10.1177/0271678X17747177 |
_version_ | 1783322968633376768 |
---|---|
author | Pauls, Mathilde MH Moynihan, Barry Barrick, Thomas R Kruuse, Christina Madigan, Jeremy B Hainsworth, Atticus H Isaacs, Jeremy D |
author_facet | Pauls, Mathilde MH Moynihan, Barry Barrick, Thomas R Kruuse, Christina Madigan, Jeremy B Hainsworth, Atticus H Isaacs, Jeremy D |
author_sort | Pauls, Mathilde MH |
collection | PubMed |
description | Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension. We reviewed published data on the effects of phosphodiesterase-5 inhibitors on CBF in adult humans. A systematic review according to PRISMA guidelines was performed. Embase, Medline and Cochrane Library Trials databases were searched. Sixteen studies with 353 participants in total were retrieved. Studies included healthy volunteers and patients with migraine, ED, type 2 diabetes, stroke, pulmonary hypertension, Becker muscular dystrophy and subarachnoid haemorrhage. Most studies used middle cerebral artery flow velocity to estimate CBF. Few studies employed direct measurements of tissue perfusion. Resting CBF velocity was unaffected by phosphodiesterase-5 inhibitors, but cerebrovascular regulation was improved in ED, pulmonary hypertension, diabetes, Becker's and a group of healthy volunteers. This evidence suggests that phosphodiesterase-5 inhibitors improve responsiveness of the cerebral vasculature, particularly in disease states associated with an impaired endothelial dilatory response. This supports the potential therapeutic use of phosphodiesterase-5 inhibitors in vascular cognitive impairment where CBF is reduced. Further studies with better resolution of deep CBF are warranted. The review is registered on the PROSPERO database (registration number CRD42016029668). |
format | Online Article Text |
id | pubmed-5951021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-59510212019-02-01 The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review Pauls, Mathilde MH Moynihan, Barry Barrick, Thomas R Kruuse, Christina Madigan, Jeremy B Hainsworth, Atticus H Isaacs, Jeremy D J Cereb Blood Flow Metab Review Articles Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension. We reviewed published data on the effects of phosphodiesterase-5 inhibitors on CBF in adult humans. A systematic review according to PRISMA guidelines was performed. Embase, Medline and Cochrane Library Trials databases were searched. Sixteen studies with 353 participants in total were retrieved. Studies included healthy volunteers and patients with migraine, ED, type 2 diabetes, stroke, pulmonary hypertension, Becker muscular dystrophy and subarachnoid haemorrhage. Most studies used middle cerebral artery flow velocity to estimate CBF. Few studies employed direct measurements of tissue perfusion. Resting CBF velocity was unaffected by phosphodiesterase-5 inhibitors, but cerebrovascular regulation was improved in ED, pulmonary hypertension, diabetes, Becker's and a group of healthy volunteers. This evidence suggests that phosphodiesterase-5 inhibitors improve responsiveness of the cerebral vasculature, particularly in disease states associated with an impaired endothelial dilatory response. This supports the potential therapeutic use of phosphodiesterase-5 inhibitors in vascular cognitive impairment where CBF is reduced. Further studies with better resolution of deep CBF are warranted. The review is registered on the PROSPERO database (registration number CRD42016029668). SAGE Publications 2017-12-19 2018-02 /pmc/articles/PMC5951021/ /pubmed/29256324 http://dx.doi.org/10.1177/0271678X17747177 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Articles Pauls, Mathilde MH Moynihan, Barry Barrick, Thomas R Kruuse, Christina Madigan, Jeremy B Hainsworth, Atticus H Isaacs, Jeremy D The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review |
title | The effect of phosphodiesterase-5 inhibitors on cerebral blood flow
in humans: A systematic review |
title_full | The effect of phosphodiesterase-5 inhibitors on cerebral blood flow
in humans: A systematic review |
title_fullStr | The effect of phosphodiesterase-5 inhibitors on cerebral blood flow
in humans: A systematic review |
title_full_unstemmed | The effect of phosphodiesterase-5 inhibitors on cerebral blood flow
in humans: A systematic review |
title_short | The effect of phosphodiesterase-5 inhibitors on cerebral blood flow
in humans: A systematic review |
title_sort | effect of phosphodiesterase-5 inhibitors on cerebral blood flow
in humans: a systematic review |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951021/ https://www.ncbi.nlm.nih.gov/pubmed/29256324 http://dx.doi.org/10.1177/0271678X17747177 |
work_keys_str_mv | AT paulsmathildemh theeffectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT moynihanbarry theeffectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT barrickthomasr theeffectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT kruusechristina theeffectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT madiganjeremyb theeffectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT hainsworthatticush theeffectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT isaacsjeremyd theeffectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT paulsmathildemh effectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT moynihanbarry effectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT barrickthomasr effectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT kruusechristina effectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT madiganjeremyb effectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT hainsworthatticush effectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview AT isaacsjeremyd effectofphosphodiesterase5inhibitorsoncerebralbloodflowinhumansasystematicreview |